Your browser doesn't support javascript.
loading
Non-motor fluctuations in Parkinson's disease: prevalence, characteristics and management in a large cohort of parkinsonian outpatients.
Brun, Lucile; Lefaucheur, Romain; Fetter, Damien; Derrey, Stéphane; Borden, Alaina; Wallon, David; Bourre, Bertrand; Maltête, David.
Afiliação
  • Brun L; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
  • Lefaucheur R; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
  • Fetter D; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
  • Derrey S; Department of Neurosurgery, Rouen University Hospital and University of Rouen, Rouen, France.
  • Borden A; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
  • Wallon D; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
  • Bourre B; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
  • Maltête D; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France; INSERM U1079, Rouen Faculty of Medicine, Rouen, France. Electronic address: david.maltete@chu-rouen.fr.
Clin Neurol Neurosurg ; 127: 93-6, 2014 Dec.
Article em En | MEDLINE | ID: mdl-25459250
OBJECTIVE: To describe demographic and clinical characteristics in a group of Parkinson's disease (PD) patients with non-motor fluctuations (NMF) and to evaluate the management of medications proposed to treat NMF. METHODS: Three hundred and three PD patients (mean age, 66 ± 10.3 years; mean disease duration, 10.1 ± 6.5 years) were enrolled. Each patient was interviewed in a non-directed fashion about the main NMF manifestations, i.e. dysautonomic, mental, and sensory symptoms. Both groups of patients with and without NMF were compared. Dysautonomia, motor fluctuations, age, disease duration, and LEDD were included in a multiple regression to determine which were predictive of NMF. RESULTS: NMF were found in 57 (19%) patients, mean age 65 ± 10.1 years, mean age at onset of PD 53.7 ± 10.9 years, mean disease duration 12.5 ± 6.9 years. NMF occurred on average 9.8 ± 7.7 years after the onset of PD. Fifty patients (86%) with NMF had also MF and 10 (21%) had PDD. Twenty-five (44%) patients suffered from sensory, 28 (49%) from autonomic and 25 (44%) from neuropsychiatric symptoms. Both disease and L-Dopa treatment durations, and LEDD were significantly higher in NMF patient's group. Motor fluctuations (p = 0.0016) and presence of dysautonomia (p = 0.007) were found to be two independent predictors of NMF. CONCLUSION: The development of new instruments to assess NMF is crucial for optimized management of advanced PD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Antiparkinsonianos Tipo de estudo: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Neurol Neurosurg Ano de publicação: 2014 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Antiparkinsonianos Tipo de estudo: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Neurol Neurosurg Ano de publicação: 2014 Tipo de documento: Article País de afiliação: França